The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader sector now triggers questions about potential returns . Copycat versions are undercutting market share, prompting anxieties that supporting companies closely tied to Viagra's previous standing could be a speculative decis